Metformin/rosuvastatin - Jeil Pharmaceutical

Drug Profile

Metformin/rosuvastatin - Jeil Pharmaceutical

Alternative Names: JLP 1310; Metformin hydrochloride/rosuvastatin calcium

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jeil Pharmaceutical
  • Class Antihyperglycaemics; Antihyperlipidaemics; Biguanides; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Cardiovascular disorders; Diabetes mellitus; Hyperlipidaemia

Most Recent Events

  • 06 Nov 2017 Jeil Pharmaceuticals completes a phase I pharmacokinetics trial in Healthy volunteers in South Korea (PO) (NCT02449187) (KCT0001497)
  • 01 Nov 2016 Jeil Pharmaceuticals initiates a phase I pharmacokinetics trial in Healthy volunteers in South Korea (PO) (NCT02982798) (NCT02449187)
  • 21 Mar 2016 Phase-III clinical trials in Cardiovascular disorders in South Korea (PO) before March 2016 (Jeil Pharmaceuticals pipeline, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top